Supplement Table 1: Characteristics of completed trials

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Study characteristics (n) | Intervention trials (n=1696) | | | Observational trials (n=424) | | |
|  | Results available (n=1357) | Results not available (n=339) | p-value | Results available (n=297) | Results not available (n=127) | p-value |
| Completed after January 1st 2008 (%) | 1154 (85.04) | 264 (77.88) | <0.01 | 289 (97.31) | 122 (96.06) | 0.54 |
| Funding source  1. NIH or Federal  2. Industry  3. Other | 123 (9.060)  654 (48.19)  580 (42.74) | 20 (5.90)  204 (60.18)  115 (33.92) | <0.001 | 22 (7.41)  83 (27.95)  192 (64.65) | 14 (11.02)  43 (33.86)  70 (55.12) | 0.16 |
| Phase  I  II  III  IV  Not known/ not applicable | 95 (7.00)  286 (21.08)  317 (23.36)  172 (12.68)  487 (35.89) | 51 (15.04)  91 (26.84)  66 (19.47)  36 (10.62)  95 (28.02) | <0.0001 | -- | -- |  |
| Clinical endpoint | 1269 (93.52) | 310 (91.45) | 0.18 | 266 (89.56) | 113 (88.98) | 0.86 |
| Intervention  1. Biologic  2. Device  3. Drug  4. Procedure  5. Other | 87 (6.41)  140 (10.32)  663 (48.86)  153 (11.27)  314 (23.14) | 7 (2.06)  20 (5.90)  216 (63.72)  32 (9.44)  64 (18.88) | <0.0001 | 6 (2.02)  14 (4.71)  11 (3.70)  27 (9.09)  239 (69.23) | 0 (0.00)  4 (3.15)  4 (3.15)  12 (9.45)  107 (84.25) | 0.58 |
| No of centers  1. Single  2. Multiple  3. Not known | 719 (52.98)  632 (46.57)  6 (0.44) | 179 (52.80)  147 (43.36)  13 (3.83) | <0.0001 | 182 (61.28)  112 (37.71)  3 (1.01) | 78 (61.42)  45 (35.43)  4 (3.15) | 0.31 |
| Trial duration in days (SD) | 1354 (929.7) | 336 (791.9) | <0.01 | 1146 (1319.8) | 882.9 (755.6) | 0.04 |

Legend: NIH, National Institute of Health; SD, Standard Deviation.